Department of Medical Biotechnology, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.
Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran.
Mutat Res Rev Mutat Res. 2021 Jan-Jun;787:108374. doi: 10.1016/j.mrrev.2021.108374. Epub 2021 Mar 26.
Among cell surface markers, CD44 is considered the main marker for identifying and isolating the cancer stem cells (CSCs) among other cells and has attracted significant attention in a variety of research areas. Many studies have shown the essential roles of CD44 in initiation, metastasis, and tumorigenesis in different types of cancer; however, the validity of CD44 as a therapeutic or diagnostic target has not been fully confirmed in some other studies. Whereas the association of specific single nucleotide polymorphisms (SNPs) in the CD44 gene and related variants with cancer risk have been observed in clinical investigations, the significance of these findings remains controversial. Here, we aimed to provide an up-to-date overview of recent studies on the association of CD44 polymorphisms and its variants with different kinds of cancer to determine whether or not it can be used as an appropriate candidate for cancer tracking.
在细胞表面标志物中，CD44 被认为是识别和分离其他细胞中的癌症干细胞（CSCs）的主要标志物，在各种研究领域引起了广泛关注。许多研究表明 CD44 在不同类型的癌症的起始、转移和肿瘤发生中起重要作用；然而，在其他一些研究中，CD44 作为治疗或诊断靶点的有效性尚未得到充分证实。虽然在临床研究中观察到 CD44 基因及其相关变体中的特定单核苷酸多态性（SNP）与癌症风险之间存在关联，但这些发现的意义仍存在争议。在这里，我们旨在提供最新的综述，介绍 CD44 多态性及其变体与不同类型癌症之间关联的研究，以确定它是否可以作为癌症追踪的合适候选标志物。
